Cyclophostin and Cyclipostins analogues counteract macrolide-induced resistance mediated by erm(41) in Mycobacterium abscessus
2024

New Compounds to Fight Antibiotic Resistance in Mycobacterium abscessus

publication 10 minutes Evidence: high

Author Information

Author(s): Sarrazin Morgane, Poncin Isabelle, Fourquet Patrick, Audebert Stéphane, Camoin Luc, Denis Yann, Santucci Pierre, Spilling Christopher D., Kremer Laurent, Le Moigne Vincent, Herrmann Jean-Louis, Cavalier Jean-François

Primary Institution: CNRS, LISM UMR7255, IMM-FR3479, Aix-Marseille Univ, Marseille, France

Hypothesis

Can Cyclipostins and Cyclophostin analogues counteract macrolide-induced resistance in Mycobacterium abscessus?

Conclusion

The study shows that Cyclipostins and Cyclophostin analogues can restore macrolide susceptibility in resistant strains of Mycobacterium abscessus.

Supporting Evidence

  • The study identified Erm(41) as a target for CyC compounds.
  • CyC compounds showed significant synergy with macrolides in restoring susceptibility.
  • Results indicate that CyC can counteract macrolide resistance mechanisms.

Takeaway

Some new medicines can help fight a tough germ that makes people sick and doesn't respond to regular antibiotics.

Methodology

The study evaluated the in vitro activity of macrolides in combination with CyC compounds using checkerboard assays on both susceptible and resistant strains of Mycobacterium abscessus.

Limitations

The study primarily focuses on in vitro results, which may not fully translate to clinical outcomes.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s12929-024-01091-w

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication